|
The Angiogenesis
Foundation
As a social enterprise, the Foundation works collaboratively to achieve
its mission. We take multidisciplinary approach with a broad range of
health stakeholders including patients, physicians, the medical research
community, drug developers, payors, government agencies, and the media,
through research, education, and the effective use of information.
Our First Decade The Foundation also developed some of the first national and international
angiogenesis conferences and courses, which were held in Washington DC,
Boston, Cambridge, London, Crete, Beijing, and Bermuda. Our early partners
in these events included NATO Advanced Study Institute, the U.S. National
Institutes of Health, Harvard Medical School, Gordon Research Conferences,
American Association for Cancer Research, American Academy of Dermatology,
Harvard Medical School, Procter & Gamble, Genentech, and the Johnson &
Johnson Company. Our conferences have attracted the participation of the
U.S. FDA, National Cancer Institute, National Eye Institute, as well as
more than 300 companies in the biotechnology, medical device and pharmaceutical
industry.
In 1997, the American Association for Cancer Research (AACR) appointed
the Foundation to represent the angiogenesis field at its national patient
advocacy event. We collaborated with doctors at Boston’s Brigham
& Women’s Hospital to start the world’s first Angiogenesis
Clinic and Wound Center in 1998 to help patients with angiogenic skin-related
conditions.
Our outreach programs have involved over 40,000 doctors, 1,000 trials,
and 10,000 patients across 30 nations worldwide.
Vision Angiogenesis, the growth of new blood vessels, is a "common denominator" shared by diseases affecting more than one billion people worldwide, including all cancers, cardiovascular disease, blindness, arthritis, complications of AIDS, diabetes, Alzheimer’s disease, and more than 70 other major health conditions affecting children and adults, in developed and developing nations. Our vision is that angiogenesis-based therapies are a unifying approach to disease and have the same impact in the 21st century that antibiotics had for disease in the 20th century. Goal Our ultimate goal is to eradicate angiogenesis-dependent diseases as
a major cause of death and suffering. This will be achieved by: harnessing
available knowledge to advance angiogenesis-based therapies, helping
patients gain access to the safest and most effective treatments, and
by applying the principles of angiogenesis for disease prevention. A Resource For Patients One of the most vital roles of the Foundation is bringing cutting edge and practical information to patients and their families. Throughout the 1990s, as angiogenesis therapies began to demonstrate their safety and efficacy in major clinical studies, patients from many countries around the world began to contact the Foundation seeking information on treatments across multiple disease areas. Educating The Medical Community The Foundation’s clinician education programs now encompass conferences, lectures, publications, and Internet-based learning. The teaching faculty is comprised of 170 leading scientific and medical experts representing different fields related to angiogenesis, including research pioneer Dr. Judah Folkman, and Nobel laureates Dr. James D. Watson and Dr. Louis J. Ignarro. Innovative Research The structure of the Foundation’s research program is based on a “spoke and wheel” model, in which research collaborations are created simultaneously with multiple external institutions. Past collaborators have included: the National Cancer Institute, NASA, Harvard Medical School, Gannon University, Massachusetts Institute of Technology, and the Johannes Gutenberg-University of Mainz, Germany. Awards The Angiogenesis Foundation received the 2006 Telly Award for excellence
of its video documentary An Answer to Cancer: Angiogenesis. It
also was awarded a Governor’s Commendation in 2003 by the Honorable
Mitt Romney, Governor of Massachusetts. Funding
As a 501(c)(3) non-profit organization, the Angiogenesis Foundation receives
funding and is supported from numerous sources, including educational grants,
charitable contributions, foundation and corporate support, and philanthropy.
Past and current funders include Aeterna-Zentaris, Bayer HealthCare Pharmaceuticals,
Bill & Melinda Gates Foundation, Celgene Corporation, Pellet Productions,
Richard E. Rainwater Charitable Trust, Rudolph & Greta Koppel Foundation,
and Thomas Bates & Associates. Expert Third Party Advocacy Impact Today Throughout the world, the Foundation has earned a reputation as the
objective third party expert on angiogenesis. Our work has been recognized
by some of the world’s most prominent figures, including Nobel Laureates
Dr. James Watson and Dr. Louis Ignarro, and Bill and Melinda Gates,
among many others. The Foundation’s body of publications includes articles
and citations in prestigious peer-reviewed journals, such as The
Lancet, Science, and The New England Journal of Medicine ,
and five medical textbooks. Top news outlets including CNN, TIME Magazine,
USA Today, FORTUNE, Wall Street Journal, MSNBC, Bloomberg News, and
The New York Times have cited the Foundation as an expert in the field. Governing Board of Directors Christopher J. Bonar, V.M.D. The Edge Nicole H. Firestone, M.B.A.
Gerald Gehr, M.D. Louis C. Hook, Jr., M.B.A. Sandra Judd, M.S. Vincent W. Li, M.D., M.B.A. William W. Li, M.D. Shawna Cornelius Li, D.V.M. Quentin Andrews Parker Daniel Rutz, M.P.H. Dimitris Tsakayannis, M.D.
Vincent W. Li, M.D., M.B.A. Derek H. Kealey Partnerships
Recent Angiogenesis Foundation collaborators have included:
The Angiogenesis Foundation
|